Denali Therapeutics
DNLI
90 hedge funds and large institutions have $1.41B invested in Denali Therapeutics in 2018 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 13 closing their positions.
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
57% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 21
15% more funds holding
Funds holding: 78 → 90 (+12)
1.09% more ownership
Funds ownership: 70.64% → 71.72% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less capital invested
Capital invested by funds: $1.46B → $1.41B (-$49.1M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$31.3M |
| 2 |
BlackRock
New York
|
+$23M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$13.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$11.5M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$5.68M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MSFP
101
Mark Sheptoff Financial Planning
Glastonbury,
Connecticut
| – | -$3K | -150 | Closed |
|
|
WSTAM
102
Wilbanks Smith & Thomas Asset Management
Norfolk,
Virginia
| – | -$3K | -150 | Closed |
|
103
Parallax Volatility Advisers
San Francisco,
California
| – | -$1K | -23 | Closed |
|
DNLI Hedge Fund Activity: Q4 2018 in Review
90 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q4 2018, worth a combined $1.41B — down 3.4% from $1.46B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new DNLI positions and 13 closed out — a net gain of 12 holders — while 33 added to existing stakes and 21 trimmed.
The largest buyer was Vanguard Group, adding an estimated $31.3M. The largest seller was Fidelity Investments, cutting an estimated $38.8M.
- 90 institutional investors held Denali Therapeutics (DNLI) as of Q4 2018, up from 78 in Q3 2018.
- Funds reported $1.41B of Denali Therapeutics stock for Q4 2018, down 3.4% quarter-over-quarter.
- 25 funds opened new Denali Therapeutics positions in Q4 2018 and 13 closed out, a net change of +12 holders.
- The largest Denali Therapeutics buyer in Q4 2018 was Vanguard Group, an estimated $31.3M added.
- The largest Denali Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $38.8M sold.
Based on aggregated 13F filings for Q4 2018.